Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia

Table 1 Ventilator settings and adverse effects during nebulization

	Control	MEM	MEM + AMK	p-value
Group size, n	39	42	42
Ventilator setting
RR (breaths/min)	24.1 ± 4.4	26.6 ± 9.7	25.6 ± 6.2	0.28
Inspiratory flow (L/min)	30.3 ± 5.6	33.7 ± 11.8	31.1 ± 7.0	0.18
PEEP (cmH₂O)	9.9 ± 1.1	8.7 ± 1.4*	9.1 ± 0.9^†	< 0.001
Adverse effects, n (%)
Coughing	2 (5.1)	1 (2.4)	1 (2.4)	0.73
Bronchoconstriction	0.0	0.0	0.0	1.00
Oxygen desaturation	0.0	0.0	2 (4.8)	0.14
Increased mucus production	26 (66.7)	32 (76.2)	31 (73.8)	0.61

Data are reported as means and standard deviations, medians (interquartile range), or (for adverse effects) the incidence among all nebulizations per group
AMK, inhaled amikacin; MEM, IV meropenem; PEEP, positive end-expiratory pressure; RR, respiratory rate
Post hoc analysis with Bonferroni correction: *p < 0.05 control versus MEM
^†p < 0.05 control versus MEM + AMK

ISSN: 1364-8535